Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.
about
Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma.Tumor angiogenesis revisited: Regulators and clinical implications.Dual Strands of Pre-miR-149 Inhibit Cancer Cell Migration and Invasion through Targeting FOXM1 in Renal Cell Carcinoma.Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma.Overexpression of CKAP4 is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma and Functions via Cyclin B Signaling.miRNAs as potential regulators of mTOR pathway in renal cell carcinoma.Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma.PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?Novel insights into biomarkers associated with renal cell carcinoma.Targeting DNA Methyltranferases in Urological Tumors.Down-regulation of transient receptor potential melastatin member 7 prevents migration and invasion of renal cell carcinoma cells via inactivation of the Src and Akt pathway.The expression and function of RASAL2 in renal cell carcinoma angiogenesis
P2860
Q33824587-F615C482-F13F-4E51-91C8-38E672E558A1Q38642100-159B2407-B404-452D-9FED-5A48007D1B62Q39393740-0B4C6630-5672-43E2-8132-97E5FEAB3010Q41660592-6A7A162F-6186-41D5-AABC-AAD584E040A4Q42288643-DF6E6010-33CC-40C6-B6AA-D9FFC1CB17E4Q47151111-171D48F2-0759-49BD-ABFD-AA093B77EC12Q47553641-AAF0166A-419E-490D-9806-702F2794E485Q48256655-C2045BFB-EBB7-4DFE-8B47-B916F7775FB6Q52728099-1647B5F8-F6A1-4006-813B-C722A86887BBQ52778165-A229F393-E4EE-49E7-AC4F-65625DC02826Q55260692-715A985F-9138-40D8-816F-EB7C9C4EEB7FQ55435258-718014BA-7FCD-4FF4-8EC0-C8D4F57BAD10Q55447540-DB0940EB-9757-444D-83F9-1E049EB23583Q58695334-7C7EAC18-9D2F-4A30-A65F-AD38F91D7DC0
P2860
Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Resistance to Targeted Therapi ...... nging the Mechanism of Action.
@en
Resistance to Targeted Therapi ...... nging the Mechanism of Action.
@nl
type
label
Resistance to Targeted Therapi ...... nging the Mechanism of Action.
@en
Resistance to Targeted Therapi ...... nging the Mechanism of Action.
@nl
prefLabel
Resistance to Targeted Therapi ...... nging the Mechanism of Action.
@en
Resistance to Targeted Therapi ...... nging the Mechanism of Action.
@nl
P2093
P2860
P50
P1433
P1476
Resistance to Targeted Therapi ...... anging the Mechanism of Action
@en
P2093
J L González-Larriba
Luis Flores
P2860
P2888
P356
10.1007/S11523-016-0463-4
P577
2017-02-01T00:00:00Z